1. Academic Validation
  2. Development of a novel AAK1 inhibitor via Kinobeads-based screening

Development of a novel AAK1 inhibitor via Kinobeads-based screening

  • Sci Rep. 2024 Mar 20;14(1):6723. doi: 10.1038/s41598-024-57051-9.
Akari Yoshida # 1 Satomi Ohtsuka # 1 Fumiya Matsumoto 2 Tomoyuki Miyagawa 2 Rei Okino 2 Yumeya Ikeda 1 Natsume Tada 1 Akira Gotoh 1 Masaki Magari 1 Naoya Hatano 1 Ryo Morishita 3 Ayano Satoh 4 Yukinari Sunatsuki 5 Ulf J Nilsson 6 Teruhiko Ishikawa 7 Hiroshi Tokumitsu 8
Affiliations

Affiliations

  • 1 Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, 700-8530, Japan.
  • 2 Department of Science Education, Graduate School of Education, Okayama University, Okayama, 700-8530, Japan.
  • 3 CellFree Sciences Co. Ltd, Matsuyama, 790-8577, Japan.
  • 4 Organelle Systems Biotechnology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, 700-8530, Japan.
  • 5 Graduate School of Natural Science and Technology, Okayama University, Okayama, 700-8530, Japan.
  • 6 Department of Chemistry, Lund University, Box 124, 221 00, Lund, Sweden.
  • 7 Department of Science Education, Graduate School of Education, Okayama University, Okayama, 700-8530, Japan. [email protected].
  • 8 Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, 700-8530, Japan. [email protected].
  • # Contributed equally.
Abstract

A chemical proteomics approach using Ca2+/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor-immobilized sepharose (TIM-063-Kinobeads) identified main targets such as CaMKKα/1 and β/2, and potential off-target kinases, including AP2-associated protein kinase 1 (AAK1), as TIM-063 interactants. Because TIM-063 interacted with the AAK1 catalytic domain and inhibited its enzymatic activity moderately (IC50 = 8.51 µM), we attempted to identify potential AAK1 inhibitors from TIM-063-derivatives and found a novel AAK1 Inhibitor, TIM-098a (11-amino-2-hydroxy-7H-benzo[de]benzo[4,5]imidazo[2,1-a]isoquinolin-7-one) which is more potent (IC50 = 0.24 µM) than TIM-063 without any inhibitory activity against CaMKK isoforms and a relative AAK1-selectivity among the Numb-associated kinases family. TIM-098a could inhibit AAK1 activity in transfected cultured cells (IC50 = 0.87 µM), indicating cell-membrane permeability of the compound. Overexpression of AAK1 in HeLa cells significantly reduced the number of early endosomes, which was blocked by treatment with 10 µM TIM-098a. These results indicate TIM-063-Kinobeads-based chemical proteomics is efficient for identifying off-target kinases and re-evaluating the kinase inhibitor (TIM-063), leading to the successful development of a novel inhibitory compound (TIM-098a) for AAK1, which could be a molecular probe for AAK1. TIM-098a may be a promising lead compound for a more potent, selective and therapeutically useful AAK1 Inhibitor.

Figures
Products